Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals logo
$452.00 -4.35 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$455.00 +3.00 (+0.66%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
4
Buy
24

Based on 29 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 1 has given a sell rating, 4 have given a hold rating, and 24 have given a buy rating for ALNY.

Consensus Price Target

$448.04
-0.88% Downside
According to the 29 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $448.04. The highest price target for ALNY is $583.00, while the lowest price target for ALNY is $220.00. The average price target represents a forecasted downside of -0.88% from the current price of $452.00.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
24 Buy rating(s)
22 Buy rating(s)
21 Buy rating(s)
17 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$448.04$417.38$341.91$279.14
Forecasted Upside-0.88% Downside-7.66% Downside7.69% Upside4.16% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.79
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-1.02% Downside1,341.23% Upside169.76% Upside
News Sentiment Rating
Positive News

See Recent ALNY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/6/2025Morgan Stanley
3 of 5 stars
Michael Ulz
Michael Ulz
Not Rated
Boost TargetEqual Weight$405.00 ➝ $475.00+4.55%
10/6/2025Stifel Nicolaus
4 of 5 stars
Paul Matteis
Paul Matteis
Not Rated
Boost TargetBuy$441.00 ➝ $495.00+8.47%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (D-)
9/19/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$435.00 ➝ $500.00+10.58%
9/17/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$453.00 ➝ $520.00+12.46%
9/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$504.00 ➝ $566.00+22.67%
9/11/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$280.00 ➝ $515.05+9.93%
9/5/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$450.00 ➝ $470.00+3.66%
9/2/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$570.00+27.55%
9/2/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$527.00 ➝ $583.00+29.48%
8/6/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$348.00 ➝ $475.00+10.95%
8/4/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$490.00+21.95%
8/4/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperformPeer Perform
8/1/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetSector Outperform$342.00 ➝ $450.00+12.00%
8/1/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$403.00 ➝ $550.00+38.02%
8/1/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$390.00 ➝ $415.00+4.88%
8/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$333.00 ➝ $395.00-0.23%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$329.00 ➝ $460.00+17.28%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$304.00 ➝ $449.00+14.47%
8/1/2025Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$325.00 ➝ $400.00+1.98%
7/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$377.00 ➝ $478.00+21.63%
7/30/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$370.00+11.93%
7/21/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00+20.11%
7/7/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$328.00 ➝ $384.00+18.58%
3/31/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$353.00+31.49%
3/21/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
1/7/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$314.00 ➝ $310.00+31.53%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$282.00 ➝ $371.00+25.37%
10/11/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$220.00 ➝ $220.00-21.77%
6/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetMarket Perform$138.00 ➝ $159.00-33.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:01 PM ET.


Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 5, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent ratings include a "buy" from Bank of America and Citigroup, suggesting potential for stock appreciation.
  • The current stock price is around $449, which is significantly higher than its 1-year low of approximately $205, indicating a strong recovery and growth potential.
  • With a market capitalization of nearly $59 billion, Alnylam Pharmaceuticals, Inc. is positioned as a major player in the biotech sector, which can attract institutional investors and enhance stock stability.
  • Twenty-four analysts have rated the stock with a "buy" rating, reflecting a consensus that the company is well-positioned for future growth and profitability.
  • The company has a solid current ratio of 2.80, indicating good short-term financial health and the ability to cover its liabilities, which is reassuring for investors.

Alnylam Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The stock has a high price-to-earnings ratio of around -182, which may indicate that the company is not currently profitable, raising concerns about its valuation.
  • Insider selling has been significant, with executives selling over 75,000 shares recently, which could signal a lack of confidence in the company's short-term prospects.
  • The company has a high debt-to-equity ratio of 4.10, suggesting that it relies heavily on debt financing, which can be risky if market conditions change.
  • Despite recent upgrades, some analysts have downgraded their ratings, indicating mixed sentiments about the company's future performance.
  • The stock has shown volatility, with fluctuations in its price, which may deter risk-averse investors looking for stable investments.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $448.04, with a high forecast of $583.00 and a low forecast of $220.00.

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 4 hold ratings and 24 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -0.88% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 2 upgrades by analysts.

Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ALNY compares to other companies.


This page (NASDAQ:ALNY) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners